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Objective: Invasive bladder cancer (IBC) is a common urological malignancy accounting for 
4%–5% of all cancers in Denmark. Our aim was to examine possible changes in short- and 
long-term survival of patients with IBC during 1998–2009.
Study design and setting: Data on all patients (N = 4032) with an incident diagnosis of 
IBC within a population of 1.8 million were retrieved from the Danish National Registry of 
Patients from 1998 to 2009. We computed survival after 1, 3, and 5 years, stratified by age and 
gender, and estimated mortality rate ratios (MRR) using Cox proportional hazard regression to 
compare mortality over time, controlling for age and gender. Data on tumor stage or histology 
were not included.
Results: During the study period, the annual numbers of incident IBC patients remained stable. 
The median age was 74 years in each of the four 3-year periods in the study. The survival 
was relatively stable during the first three periods, whilst data from the last period showed 
  modest improvement. The overall 1-year survival increased from 68% in 1998–2000 to 70% 
in 2007–2009, corresponding to an age and gender adjusted MRR of 0.89 (95% confidence 
interval [CI] 0.76–1.03). The 3- and 5-year survival was predicted to increase from 44% to 
49% and from 35% to 40% respectively. This corresponded to a 3-year age and gender adjusted 
MRR of 0.87 (95% CI 0.77–0.98) and a 5-year MRR of 0.88 (95% CI 0.79–0.99). The 1-, 3-, 
and 5-year survival increased for men in all age groups (,70 years, 70–79 years, $80 years) 
and in women only in the 70–79-year age group. 
Conclusion: The survival of IBC patients increased slightly in northern and central Denmark 
in the 1998–2009 period.
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Introduction
Bladder cancer is the fourth most common cancer in men and ninth most common cancer 
in women, with 68,000 new cases and 14,000 deaths estimated in the United States in 
2008.1 In Denmark, the annual incidence was 27/100,000 in 2009 thereby accounting for 
4%–5% of all cancers.2 A number of studies have reported that the prognosis after early 
stage (Ta, T1) bladder cancer is good,3–7 with a 5-year survival exceeding 75%.7 However, 
we have previously shown that the overall 1-year survival following bladder cancer in a 
Danish regional population-based setting, including both early and late stage cancers, 
was only around 65% and 5-year survival was around 35%.8 Of major concern, our previ-
ous study also showed that the survival did not improve substantially in the 1996–2007 
period. Such lack of increase in survival was supported by a nationwide population-
based Danish study, which reported unchanged one-year relative (age standardized) Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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survival estimates for the 1995–2006 period.9 Furthermore, 
the EUROCARE-4 study including cancer cases from can-
cer registries in 23 European countries reported that Danish 
bladder cancer patients diagnosed in 1995–1999 had an 
age-standardized 5-year relative survival of 68.9 (95% confi-
dence interval [CI] 67.5–70.3) compared with a 5-year rela-
tive survival of 72.4 (95% CI 71.9–72.8) combined for the 23 
countries.10 These results of a lower survival among Danish 
bladder cancer patients were supported by a more recent Nordic 
study including data through 2003.11 The reasons for a lower 
survival in Denmark than in other western European countries 
remain unknown. To improve survival for cancer in Denmark 
in general, the Danish government implemented National 
Cancer Plans in 2000 and 2005 with the aim to diagnose and 
treat patients with cancer at an earlier stage.12
We therefore conducted the present study to monitor sur-
vival in Danish invasive bladder cancer (IBC) patients during 
the period in which these plans were introduced.
Materials and methods
We conducted this study in the central and the northern 
Denmark regions, with a combined population of 1.8 million 
persons. The National Health Service provides tax-supported 
health care for all inhabitants of Denmark, guaranteeing free 
access to hospitals. In Denmark, all bladder cancer patients 
are seen at a hospital by a specialist in urology who takes 
care of their treatment. Virtually no bladder cancer patients 
were treated in private hospitals during the study period. 
The surgical and oncological treatment is centralized to only 
five hospitals.
Identification of bladder cancer patients
Through the Danish National Registry of Patients (DNRP), 
we identified all patients who had a first-time hospitalization 
with bladder cancer in the period January 1, 1998 through 
December 31, 2009. The DNRP contains information about 
all admissions from nonpsychiatric hospitals in Denmark since 
1977.13 Outpatient and emergency room visits at hospitals have 
been included since 1995. This registry includes information 
on civil registration number, dates of admission and discharge, 
surgical procedure(s) performed, and up to 20 diagnoses from 
each hospital contact. Diagnoses have been classified accord-
ing to the International Classification of Diseases 10th edition, 
and the code used to identify bladder cancer was C67.
Follow-up
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit personal identification number 
to all Danish citizens.14 This number, unique to each Danish 
resident, is used in all Danish registries, allowing unambigu-
ous individual-level data linkage. From the Civil Registration 
System we also obtained information on vital status (dead or 
alive), date of death, and residence for all cancer patients.
Statistical analysis
We followed each patient from date of cancer diagnosis until 
emigration, death, or 25 June, 2010, whichever came first. 
To visualize crude survival, we constructed   Kaplan–Meier 
curves stratified according to period of diagnosis 
(1998–2000, 2001–2003, 2004–2006, and 2007–2009). In 
the latter periods, we estimated 3- and 5-year survival using 
a hybrid analysis in which we included the actual survival 
for as long as possible and then estimated the conditional 
probability of surviving thereafter based on the correspond-
ing survival experience of patients in the previous period (ie, 
using a period analysis technique).15 To compare mortality 
over time, we used Cox proportional hazards regression 
analysis, with 1998–2000 as the reference period to estimate 
1-, 3-, and 5-year mortality rate ratios (MRRs) and corre-
sponding 95% CIs, adjusting for age group (15–69, 70–79, 
80+ years) and gender. Analyses were performed using SAS 
version 9.2 (SAS Institute Inc, Cary, NC).
Results
Descriptive data
We identified 4032 patients (2992 men and 1040 women) 
with a new diagnosis of IBC between 1998 and 2009. Median 
age at cancer diagnosis was 74 years (range 33–96 years). 
The annual number of bladder cancer patients remained stable 
during the study period (Table 1).
Survival
The overall 1-year survival increased slightly from 68% in 
1998–2000 to 70% in 2007–2009, corresponding to an age and 
gender adjusted MRR of 0.89 (95% CI 0.76–1.03)   (Figure 1 
and Table 1). The 3- and 5-year survival is predicted to increase 
from 44% to 49% and from 35% to 40%, respectively. This 
corresponded to a 3-year age- and gender-adjusted MRR of 
0.87 (95% CI 0.77–0.98) and a 5-year MRR of 0.88 (95% CI 
0.79–0.99) in the 2007–2009 period (Table 1).
With few exceptions, particularly among the younger 
women, the 1-, 3-, and 5-year survival increased over the 
study period across age groups and gender (Tables 2 and 3). 
In general, men had a slightly higher 1-year survival than 
females. For instance, 82% of 15–69-year-old men survived 
1 year after the cancer diagnosis in the 2007–2009 periods, Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 1 1-, 3-, and 5-year survival, and the crude, gender- and age-adjusted 1-, 3-, and 5-year all-cause Mrrs in the four time periods. 
The reference was patients from the period 1998–2000
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 1028 960 965 1079
Median age (years) 73 74 74 74
1 year
Survival 68% (65%–70%) 63% (60%–66%) 64% (61%–67%) 70% (67%–73%)
Mrrs 1 (reference) 1.18 (1.02–1.37) 1.16 (0.99–1.34) 0.91 (0.78–1.06)
Adjusted Mrrsa 1 (reference) 1.17 (1.01–1.36) 1.16 (1.00–1.34) 0.89 (0.76–1.03)
3 year
Survival 44% (41%–47%) 42% (39%–45%) 43% (40%–46%) 49% (46%–52%)b
Mrrs 1 (reference) 1.07 (0.96–1.21) 1.04 (0.93–1.17) 0.88 (0.78–0.99)b
Adjusted Mrrsa 1 (reference) 1.07 (0.95–1.20) 1.05 (0.94–1.18) 0.87 (0.77–0.98)b
5 year
Survival 35% (32%–38%) 33% (30%–36%) 35% (32%–38%)b 40% (37%–43%)b
Mrrs 1 (reference) 1.08 (0.97–1.20) 1.03 (0.93–1.15)b 0.89 (0.80–0.99)b
Adjusted Mrrsa 1 (reference) 1.08 (0.97–1.20) 1.05 (0.94–1.17)b 0.88 (0.79–0.99)b
Notes: The corresponding 95% confidence intervals are given in parentheses. aAdjusted for age and gender; bPredicted values.
Abbreviation: Mrr, mortality rate ratio.
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Figure 1 Overall survival in Danish invasive bladder cancer patients diagnosed in the period 1998–2009 in two of five Danish regions.
while only 64% of women of the same age were alive after 
1 year. In this younger age group, the 3- and 5-year survival 
was also highest in men, while the 3- and 5-year survival was 
virtually similar in men and women more than 70 years of 
age at least in the 2007–2009 periods.
Discussion
In this population-based cohort study we found that the mor-
tality of IBC decreased by approximately 10% comparing 
2007–2009 with 1998–2000. However, for women younger 
than 70 years of age the survival remained stable and was 
lower than the survival in men younger than 70 years at 
study end.
Several factors should be considered when interpreting 
our results. The validity of our results is to a large degree 
dependent on our ability to identify the IBC population and 
to the reliability of our follow-up information. Denmark has 
a uniformly organized public health care system that allowed 
for a population-based design with complete long-term 
follow-up for mortality. We included all admitted-patient 
and out-patient visits at hospitals with bladder cancer from 
two Danish regions in the study. Still, it is well known that 
the coding of hospital diagnoses may not always be accurate. 
However, the cancer diagnoses in the DNRP have generally 
been reported to have a high validity.16 A weakness of our 
study, however, is the absence of specific tumor pathologic Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 2 1-, 3-, and 5-year survival in men with bladder cancer in the four time periods, examined by age
Men Year of diagnosis
Age (years) 1998–2000 2001–2003 2004–2006 2007–2009
15–69
  number of cancer patients [%] 299 [39%] 252 [36%] 268 [37%] 299 [37%]
  1-year survival 78% (73%–82%) 79% (73%–84%) 85% (80%–88%) 82% (77%–86%)
  3-year survival 61% (55%–66%) 60% (54%–66%) 67% (61%–72%) 67% (61%–72%)a
  5-year survival 55% (49%–60%) 52% (46%–58%) 58% (52%–64%)a 57% (51%–63%)a
70–79
  number of cancer patients [%] 293 [38%] 258 [37%] 275 [38%] 298 [37%]
  1-year survival 74% (69%–79%) 66% (60%–72%) 65% (59%–70%) 77% (72%–82%)
  3-year survival 46% (40%–52%) 45% (39%–51%) 42% (36%–48%) 48% (42%–54%)a
  5-year survival 33% (28%–39%) 36% (30%–41%) 34% (29%–40%)a 39% (33%–45%)a
80+
  number of cancer patients [%] 181 [23%] 182 [26%] 186 [26%] 201 [26%]
  1-year survival 51% (44%–58%) 48% (40%–55%) 45% (37%–52%) 57% (50%–63%)
  3-year survival 25% (19%–31%) 24% (18%–30%) 22% (16%–28%) 30% (24%–37%)a
  5-year survival 15% (11%–21%) 14% (10%–20%) 14% (9%–19%)a 19% (13%–26%)a
Notes: The corresponding 95% confidence interval is given in parentheses. aPredicted values.
Table 3 1-, 3-, and 5-year survival in women with bladder cancer in the four time periods, examined by age
Women Year of diagnosis
Age (years) 1998–2000 2001–2003 2004–2006 2007–2009
15–69
  number of cancer patients [%] 98 [38%] 102 [38%] 83 [35%] 88 [31%]
  1-year survival 68% (58%–77%) 70% (60%–78%) 65% (54%–74%) 64% (53%–74%)
  3-year survival 44% (34%–53%) 48% (38%–57%) 45% (34%–55%) 42% (31%–52%)a
  5-year survival 42% (32%–51%) 40% (30%–49%) 39% (29%–50%)a 37% (27%–47%)a
70–79
  number of cancer patients [%] 87 [34%] 95 [35%] 83 [35%] 106 [38%]
  1-year survival 56% (45%–66%) 55% (44%–64%) 60% (49%–70%) 72% (62%–80%)
  3-year survival 31% (22%–41%) 39% (29%–49%) 42% (31%–52%) 52% (42%–61%)a
  5-year survival 26% (18%–36%) 28% (20%–38%) 32% (22%–42%)a 40% (29%–50%)a
80+
  number of cancer patients [%] 70 [27%] 71 [26%] 70 [30%] 87 [31%]
  1-year survival 49% (36%–60%) 31% (21%–42%) 30% (20%–41%) 43% (33%–54%)
  3-year survival 24% (15%–35%) 8% (3%–16%) 14% (7%–23%) 31% (20%–42%)a
  5-year survival 17% (9%–27%) 4% (1%–11%) 7% (2%–17%)a 18% (5%–36%)a
Notes: The corresponding 95% confidence interval is given in parentheses. aPredicted values.
data such as histological pattern of tissue differentiation and 
tumor stage. Thus, we were unable to evaluate whether the 
improvement in survival stemmed from changes over the 
study period in any of these factors. Nevertheless, if improved 
diagnostic techniques over time have resulted in changes 
in stage classification (ie, stage migration) stage-specific 
  survival could be biased.17 On the other hand, changes in stage 
distribution may be part of the causal pathway to improved 
survival over time, and if so, adjustment for stage could be 
inappropriate. However, results from the Danish Bladder 
Cancer Registry Group’s yearly report,18 which is based on 
detailed data from the Danish Pathology Registry, have shown 
that neither cancer histology nor cancer stage has changed 
substantially over the study period.
In a previous study from our region, we found that   survival 
in IBC patients had not appreciably altered in Denmark in 
the 1995–2004 period.8 The newly implemented National 
Cancer Plan12 was initiated to improve health care organi-
zation including faster and easier availability of   diagnostic 
follow-up and treatment. Accordingly, cancer surgery, 
chemotherapy, and radiation have been centralized to fewer 
specialized centers. Furthermore, new diagnostic procedures 
such as photodynamic procedures have been implemented, 
and the surgical techniques have become less invasive with 
better equipment and instruments.19 Recent nationwide data 
from the USA in the period 2003–2007 including 40,388 
patients with IBC confirmed improvements in process of 
care measures in patients who underwent cystectomy.20 Clinical Epidemiology
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The proportion of patients treated with cystectomy (42.9%) 
and radiation therapy (16.6%) remained stable with time, 
while the proportion of those who received chemotherapy 
increased from 27.0% in 2003 to 34.5% in 2007.20
The improvement in survival, irrespective of gender, 
among patients aged 70+ years could partly be due to a 
change in life expectancy in the Danish population during 
the study period. In the two nationwide studies,9,11 which 
included Danish data and reported relative survival estimates 
(relative to the background population), the survival seemed 
not to improve in the most recent years, indicating that it may 
be the general life expectancy more than a specific improve-
ment in bladder cancer survival that caused the observed 
increase in survival in our study. However, these studies 
only included data through 200311 and 2006,9 respectively, 
and we only observed the survival improvement in the later 
2007–2009 period. In addition, we also find it unlikely that the 
life expectancy has increased substantially within just a few 
years. Therefore, although we cannot rule out completely that 
changes in life expectancy had influence on our estimates, we 
find it unlikely that this was the main explanation.
In conclusion, our study showed that the survival of IBC 
patients increased slightly in northern and central Denmark 
in the 1998–2009 period.
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